Ignite Creation Date:
2024-05-05 @ 11:38 AM
Last Modification Date:
2024-10-26 @ 9:11 AM
Study NCT ID:
NCT00095394
Status:
COMPLETED
Last Update Posted:
2011-04-15
First Post:
2004-11-03
Brief Title:
IrbesartanHydrochlorothiazide HCTZ Combination Therapy as First Line Treatment for Severe Hypertension
Sponsor:
Bristol-Myers Squibb
Organization:
Bristol-Myers Squibb
Study Overview
Official Title:
The Efficacy and Safety of IrbesartanHCTZ Combination Therapy as First Line Treatment for Severe Hypertension
Status:
COMPLETED
Status Verified Date:
2008-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this clinical research is to learn if severe hypertension can be better controlled by initially treating with a combination of drugs IrbesartanHCTZ in patients who are unlikely to achieve blood pressure BP control with only one drug In addition the study will also evaluate the safety and tolerability of the drugs
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None